Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-101 in Acute Peripheral Tinnitus (TACTT2)
NCT01803646Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Feb 2014
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Keyzilen in tinnitus, sponsored by Altamira Therapeutics. Primary endpoint: Patient-reported Tinnitus Loudness Questionnaire Improvement at 83 days. Started Feb 2014; status: completed.
02
Drugs
Keyzilen
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT01803646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01803646.